Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
复制标题
DOI：
10.1093/annonc/mdm448
复制
发表时间：
2008-02-01
影响因子：
50.5
通讯作者：
Corazza, G. R.
中科院分区：
文献类型：
--
作者：
Porta, C.;De Amici, M.;Corazza, G. R.
背景资料：大量的证据表明，白细胞介素-6（IL-6）在肝细胞癌（HCC）的发病机制中可能发挥作用。患者和方法：我们研究了HCC患者、非肿瘤性肝病患者和健康对照者的IL-6和A，FP。至于甲胎蛋白（A（1）FP）滴度，在癌症患者中观察到最高水平。受试者工作特征（ROC）曲线分析表明IL-6比A（1）FP具有更强的区分性，“最佳”截止值为7.9 pg/ml（灵敏度= 0.83，特异性= 0.83，效率= 0.83）。用于区分HCC和单纯HCC患者的ROC曲线显示IL-6与A（1）FP滴度相比具有更高的判别能力，新的临界值为12 pg/ml（灵敏度=0.73，特异性=0.87，效率=0.8）。对HCC和非HCC受试者的判别分析的敏感性、特异性和有效率分别为77%、93%和88%。结论：IL-6是一种有前景的肝癌标志物。特别是，当与A（1）FP结合时，该测试的诊断价值显着增加。
Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC).Patients and methods: We studied both IL-6 and A, FP in patients with HCC, non-neoplastic liver disease or in healthy controls.Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alphal-fetoprotein (A(1)FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A(1)FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A(1)FP titers, with a new cut-off value of 12 pg/ml (sensitivity=0.73, specificity=0.87, efficiency=0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%.Conclusions: IL-6 could be considered a promising tumor marker for HCC. In particular, the diagnostic value of the test is significantly increased when combined with A(1)FP.